Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. (EGC102)

A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer

The purpose of this research study is to compare the efficacy and safety of EG1206A with Perjeta in combination with trastuzumab and chemotherapy as neoadjuvant treatment for 18 weeks, followed by surgery and subsequent EG1206A or Perjeta in combination with trastuzumab, as adjuvant treatment for 36 weeks.

Study Overview

• Status: Withdrawn
• Conditions: Early Breast Cancer
• Intervention / Treatment: Drug: EG1206A; Drug: Perjeta

• Study Type: Interventional
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Texas
    • Dallas, Texas, United States, 75023
      • Methodist Health System Clinical Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Inclusion Criteria (before randomization)

Patients are eligible to be included in the study only if all of the following criteria apply:

1. Provide signed and dated written informed consent before any study related procedures are performed. The informed consent will cover both parts of the study (neoadjuvant part and adjuvant part).
2. Female and male patients ≥ 18 and ≤ 70 years of age.
3. Histologically-confirmed invasive carcinoma of the breast.
4. Early stage (T2-3, N0-1, M0), locally advanced stage (T2-3, N2-3, M0 or T4a-c, any N, M0), or inflammatory (T4d, any N, M0) breast cancer planned for surgical resection (mastectomy or lumpectomy of the breast, and resection of sentinel or axillary lymph nodes).
5. Unilateral, measurable tumor of the breast > 2 cm in diameter (by ultrasound and/or mammography).
6. HER2-positive tumor status (according to American Society of Clinical Oncology/College of American Pathologists [ASCO/CAP] guidelines [2018, 2023]), as confirmed by central laboratory.
7. Estrogen receptor and progesterone receptor-negative tumor (according to ASCO/CAP guidelines [2020]), as confirmed by central laboratory.
8. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
9. Baseline left ventricular ejection fraction (LVEF) ≥ 55%, measured by echocardiography or MUGA (multigated acquisition scan).
10. Adequate bone marrow function, defined as neutrophil count of ≥ 1,500/µL, hemoglobin ≥ 9 g/dL, and platelet count of ≥ 100,000/µL.
11. Adequate hepatic and renal function, defined as total bilirubin ≤ 1.5 × upper limit of normal (ULN) (or ≤ 3 × ULN and direct bilirubin within normal limits in patients with well documented Gilbert's syndrome), alanine aminotransferase (ALT) ≤ 3 × ULN, aspartate aminotransferase (AST) ≤ 3 × ULN, creatinine clearance ≥ 30 mL/min (according to Cockcroft and Gault equation).
12. International normalized ratio ≤ 1.5 × ULN (2 to 3 × ULN if on anticoagulants with vitamin K antagonists) or prothrombin time ≤ 1.5 × ULN; activated partial thromboplastin time ≤ 1.5 × ULN.
13. For women of childbearing potential (WOCBP): WOCBP must have a negative serum pregnancy test at Screening and must use adequate birth control. Adequate birth control is defined as agreement to consistently practice an effective and accepted method of contraception throughout the duration of the study and for 7 months after the End of Treatment (EOT) Visit. These methods include hormonal contraceptives, intrauterine device, or double barrier contraception (i.e., condom + diaphragm) or a male partner with documented vasectomy. Non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

14. For men: Men must agree to use reliable contraceptive measures throughout the duration of the study and for 7 months after the EOT Visit. These methods include documented vasectomy, double-barrier contraception (i.e., condom and diaphragm), or true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient).

    Inclusion Criteria (after surgery for the adjuvant part of the study)

15. Patients with complete pathological remission.
16. Patients with residual disease that cannot receive further treatment with trastuzumab emtansine (in case of contraindication to trastuzumab emtansine, recommendations from local guidelines, or at the discretion of the Investigator).

Exclusion Criteria:

1. Stage IV (metastatic) breast cancer, bilateral breast cancer.
2. Pregnancy or lactation or considering becoming pregnant.
3. Previous treatment (chemotherapy, biologic therapy, radiation, or surgery) for invasive malignant disease or other concomitant malignancy, other than basal cell carcinoma of the skin. Previous treatment for carcinoma in situ of the cervix is allowed.
4. Previous treatment with Perjeta.
5. Active hepatitis B or hepatitis C infection, or infection with the human immunodeficiency virus (HIV) as shown by a positive diagnostic test for hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV.
6. History of or existing congestive heart failure (CHF) New York Heart Association class II or higher; angina pectoris or arrhythmia requiring medication; poorly controlled hypertension; history of myocardial infarction or cardiac failure; clinically significant cardiac valvular disease; hemodynamic effective pericardial effusion; other cardiomyopathies.
7. Any investigational treatment less than 30 days prior to study entry, or within a time interval less than at least 5 half-lives of the investigational medicinal product (IMP: EG1206A or Perjeta), whichever is longer.
8. Hypersensitivity to the IMP (EG1206A or Perjeta), trastuzumab or trastuzumab biosimilar, carboplatin (or other platin compounds), and docetaxel, or to any of their excipients.
9. Vaccination with live attenuated vaccines during the study.
10. History of, or known current problems with, drug or alcohol abuse.
11. Other serious illness, previous surgery (other than for invasive malignant disease), medical disorder or condition that, in the opinion of the Investigator, would make the patient unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EG1206A; During the neoadjuvant treatment period, patients will receive 6 cycles with EG1206A, trastuzumab, and chemotherapy (docetaxel and carboplatin), followed by surgery. If criteria to remain on study are still fulfilled, patients will continue treatment in the adjuvant setting, starting 2 to 6 weeks after surgery. Patients will receive 12 cycles with EG1206A and trastuzumab (as originally randomized in the neoadjuvant part) to complete 1 year of HER2-targeted therapy.	Drug: EG1206A; EG1206A 420mg is ongoing to be administered after 840mg loading dose.
Active Comparator: Perjeta; During the neoadjuvant treatment period, patients will receive 6 cycles with Perjeta, trastuzumab, and chemotherapy (docetaxel and carboplatin), followed by surgery. If criteria to remain on study are still fulfilled, patients will continue treatment in the adjuvant setting, starting 2 to 6 weeks after surgery. Patients will receive 12 cycles with Perjeta and trastuzumab (as originally randomized in the neoadjuvant part) to complete 1 year of HER2-targeted therapy.	Drug: Perjeta; Perjeta 420mg is ongoing to be administered after 840mg loading dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of pathologic complete response (pCR) at time of surgery	• pCR at time of surgery, where pCR is defined as the absence of residual invasive cancer of the complete resected breast specimen (regardless of ductal carcinoma in situ [DCIS]) and all sampled sentinel and/or axillary lymph nodes (ypT0/is ypN0), as assessed by central laboratory.	At the time of surgery (3-6 weeks after completion of neoadjuvant chemotherapy)

Collaborators and Investigators

• Sponsor: EirGenix, Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2025
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: March 18, 2025
• First Submitted That Met QC Criteria: March 18, 2025
• First Posted (Actual): March 19, 2025

Study Record Updates

• Last Update Posted (Estimated): October 14, 2025
• Last Update Submitted That Met QC Criteria: October 10, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms; Antineoplastic Agents, Immunological; Antineoplastic Agents; pertuzumab
• Other Study ID Numbers: EGC102; 2024-518619-21-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No